OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
PTSM: Pharmaceutical Technology Sourcing and Management
The company invested SEK 72 million ($9 million) to expand manufacturing capacity at its Karlskoga facility in Sweden.
On September 6, 2016, Cambrex Corporation, a manufacturer of small molecule innovator and generic APIs, announced a SEK 72 million ($9 million) investment to expand manufacturing capacity at its Karlskoga facility in Sweden. The investment includes the installation of new multi-purpose reactors and a control room upgrade. The new facilities will undergo validation and cGMP qualification ahead of the operational start up in Q4 2016. The expansion at Cambrex’s Swedish site is part of an ongoing campaign to invest in small molecule API manufacturing across its global network of facilities.
“Our facility at Karlskoga is strategically important, both in Scandinavia and the wider European markets, and this investment is in response to an increase in demand for larger scale, multi-purpose manufacturing capabilities,” Bjarne Sandberg, managing director, Cambrex Karlskoga said in a statement. “By creating greater capacity within the current infrastructure, we have combined expansion and efficiency at the site, both of which will benefit our customers.”